Brand and Other Names:INFeD, Dexferrum
- Classes: Iron Products
Dosing & Uses
Dosage Forms & Strengths
- 50mg (Fe)/mL
25-100 mg IV or deep IM qDay PRN
Not to exceed 100 mg (2 mL)/day
Iron deficiency: Dose = 0.0442(Desired Hgb - Observed Hgb) x Lean BW(kg) + (0.26 × Lean BW)
Blood loss: total iron dose in mg = blood loss (mL) x HCT
Dosage Forms & Strengths
- 50mg (Fe)/mL
Not to be given in first 4 months of life
Dose = 0.0442(Desired Hgb - Observed Hgb) x BW(kg) + (0.26 × BW)
Desired hemoglobin usually 12 g/dL
>15 kg: 0.0442(Desired Hgb - Observed Hgb) x Lean BW(kg) + (0.26 × Lean BW)
Serious - Use Alternative
Significant - Monitor Closely
Brown discoloration of skin
Frequency Not Defined
Black Box Warnings
Anaphylactic type reactions, sometimes fatal, have occurred with parenteral use of this product. Reserve for use only in patients with laboratory-confirmed iron deficiency who are unable to take oral iron.
Anemia not associated with iron deficiency
Acute phase of infectious renal disease
Use caution in rheumatoid arthritis, HIV+ patients, history of allergies, history of asthma, severe hepatic impairment, preexisting cardiovascular disease
May increase pathogenicity of certain microorganisms
May induce hemosiderosis if used for non-iron-deficiency anemia
Pregnancy & Lactation
Pregnancy Category: C
Lactation: traces excreted in breast milk, use caution
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Replacement of iron stores found in hemoglobin, myoglobin, and enzymes; works to transport oxygen via hemoglobin
Half-Life: 6 hr
Onset: 7-9 days (serum ferritin peak)
Peak Plasma Time: 10 days
Absorption: Within 72 hr (IM)
Excretion: Minimal through urine and feces
Standard diluent: dose/250-1000 mL NS
Minimum volume: 250 mL NS
IM: use z-track technique for IM administration (deep into upper outer quadrant of buttock)
IV may be administered bolus at <50 mg/min or diluted in 250-1000 mL NS & infused over 1-6 hr
Infuse initial 25 mL slowly, observe for allergic reactions
Have epinephrine nearby
Store at room temp
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Select a box to add or remove a plan.
Select a class to view formulary status for similar drugs